Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Previously Untreated Elderly NSCLC
NCT00864721Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- Feb 2009
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by US Oncology Network. Primary endpoint: Disease Control Rate up to 36 months. Started Feb 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00864721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00864721.